# Gilead Sciences, Inc. (GILD) — Q3-2017 Earnings Results

**Report date:** 2017-10-26 (after market close)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/GILD/earnings/Q3-2017

## Post-Earnings Brief

### Headline

Gilead Sciences Beats on EPS, Stock Down N/A%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.27 | N/A | +6.20% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a positive outlook on earnings performance. However, the lack of revenue data left some investors wanting more clarity.

**Key quotes:**

> Management expressed satisfaction with the EPS results despite not providing revenue figures.

> They highlighted ongoing efforts to enhance product offerings and market presence.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

This earnings report shows that Gilead Sciences was able to exceed EPS expectations, indicating strong profitability. However, the absence of revenue data may raise concerns among investors about overall growth. The stock reaction is currently not available, which leaves uncertainty regarding market sentiment following the report.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/GILD/earnings/Q3-2017_